5-amino-1-(N-methylcarbamoyl)imidazole-4-carboxamide

We are 5-amino-1-(N-methylcarbamoyl)imidazole-4-carboxamide CAS:188612-53-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 5-amino-1-(N-methylcarbamoyl)imidazole-4-carboxamide
CAS.NO:188612-53-5
Synonyms:
1H-Imidazole-1,4-dicarboxamide, 5-amino-N-methyl-
5-amino-n-1-methyl-1h-imidazole-1,4-dicarboxamide
5-Amino-N-methyl-1H-imidazole-1,4-dicarboxamide

Molecular Formula:C6H9N5O2
Molecular Weight: 183.16800

Physical and Chemical Properties:
Density:1.7±0.1 g/cm3
Boiling point: /
Melting point: /
Flash point:/
Refractive index: 1.728

Specification:
Appearance: White  powder
Purity:≥99%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Temozolomide CAS:85622-93-1

Related News: In addition, due to the complex process of changing the API supplier and the risk of uncertainty, the viscosity of pharmaceutical and specialty API companies is usually better.164298-23-1 APIs are generally manufactured through a variety of processes that include.3-methyl-5-nitropyridin-2-amine CAS:18344-51-9 In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.Tetrafluoroborato de O- (5-norborneno-2,3-dicarboximido) -N, N, N ', N′-tetrametiluronio CAS:125700-73-4 Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries.Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).